duloxetine hydrochloride + placebo

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Fibromyalgia

Conditions

Fibromyalgia

Trial Timeline

Jun 1, 2008 → Jul 1, 2009

NCT ID

NCT00673452

About duloxetine hydrochloride + placebo

duloxetine hydrochloride + placebo is a approved stage product being developed by Eli Lilly for Fibromyalgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00673452. Target conditions include Fibromyalgia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00673452	Approved	Completed	Jun 1, 2008	Jul 1, 2009	Fibromyalgia
NCT00536471	Approved	Completed	Sep 1, 2007	Dec 1, 2008	Major Depressive Disorder
NCT00422162	Approved	Completed	Feb 1, 2007	Aug 1, 2008	Major Depressive Disorder
NCT00408993	Phase 3	Completed	Dec 1, 2006	Feb 1, 2008	Diabetic Neuropathies
NCT00406848	Approved	Completed	Nov 1, 2006	Nov 1, 2009	Major Depressive Disorder
NCT00244296	Approved	Completed	Oct 1, 2005	Jan 1, 2007	Urinary Incontinence, Stress
NCT00191919	Phase 3	Completed	May 1, 2005	May 1, 2006	Depressive Disorder, Major
NCT00122863	Phase 3	Completed	Jan 1, 2005	Mar 1, 2007	Anxiety Disorders
NCT00122824	Phase 3	Completed	Jun 1, 2004	Sep 1, 2005	Anxiety Disorders
NCT00190996	Phase 3	Completed	Jan 1, 2003	Jun 1, 2006	Urinary Incontinence, Stress
NCT00058968	Phase 3	Completed	Oct 1, 2002	Mar 1, 2005	Diabetic Neuropathy, Painful

Competing Products

20 competing products in Fibromyalgia

See all competitors

Product	Company	Stage	Hype Score
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	77
DS-5565	Daiichi Sankyo	Phase 3	77
DS-5565 + Placebo	Daiichi Sankyo	Phase 3	77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	77
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	77
ASP8062 + Placebo	Astellas Pharma	Phase 2	52
ASP0819 + Placebo	Astellas Pharma	Phase 2	52
Duloxetine	Shionogi	Phase 3	77
Duloxetine 60 mg + Placebo	Shionogi	Phase 3	77
zonisamide	Eisai	Approved	85
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	52
Duloxetine	Eli Lilly	Approved	85
duloxetine	Eli Lilly	Phase 3	77
Duloxetine + placebo	Eli Lilly	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Approved	85
Treatment for Fibromyalgia	Eli Lilly	Pre-clinical	23
Duloxetine + Placebo	Eli Lilly	Phase 3	77
duloxetine + placebo	Eli Lilly	Phase 3	77
Eszopiclone + placebo	Sumitomo Pharma	Approved	85

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved